Kornimate/medical-research-clean huggingface dataset:
mdixon tse mri sequence and conventional mri sequences in dysimmune orbitopathies (ddx)

Conditions: Dysthyroid Ophthalmopathies

Summary: the dysthyroid orbitopathy (do) is a chronic disease, evolving during 2 to 3 years, with a hypertrophy and a variable degree of inflammation of the eyelid muscles, the oculomotor muscles and the orbital fat. if the diagnosis of od is primarily clinical and laboratory, mri is an additional contribution to the clinic, guiding the therapeutic management by detecting inflammatory lesions not found on clinical examination in 1/3 of cases. the three mri sequences conventionally practiced ((t2, t2-fat-sat, t1) allow muscles signal analysis oculomotor abnormalities as well as the orbital fat. compared to these sequences, the main advantage sequences dixon is a faster acquisition. in addition, dixon type of imaging overcomes most of these artifacts and to obtain a homogeneous fat removal.


Eligibility criteria:
inclusion criteria: * patient aged 18 to 90 years, suffering from thyroid dysfunction proved by clinical and laboratory tests, with a bilateral clinical dysthyroid orbitopathy and undergoing an eye mri exclusion criteria: * absolute or relative contra-indication to mri or to a contrast agent gadolinium injection (including pregnant or likely to be, breastfeeding women) * patient under guardianship * patient not willing to participate. * lack of affiliation to social security or medical state aid (ame) or universal health coverage (cmu) * motion artifact on the sequences, not corrected by the repeat sequences * metal artifact prohibiting the analysis of the region of interest
comparison of efficacy and frequency of adverse events of 1st line palliative chemotherapy eox and mdcf regimens in advanced her2-negative gastric carcinoma

Conditions: HER2 Negative Gastric Cancer

Summary: the purpose of the study is to compare efficacy and safety of palliative chemotherapy eox and mdcf regimens in the first-line treatment of patients with advanced her2-negative gastric and gastroesophageal junction (gej) adenocarcinoma

the main purposes: to determine the overall survival (os) of patients who have locally advanced inoperable or metastatic her2-negative gastric and gastroesophageal adenocarcinoma treated with first-line eox (epirubicin + oxaliplatin + capecitabine) or mdcf (docetaxel + cisplatin + leucovorin + 5fluorouracil) palliative chemotherapy regimens the secondary purposes: to determine safety (as assessed by adverse events according to the common terminology criteria for adverse events (ctcae) v4.0) and the progression-free survival (pfs)

Eligibility criteria:
inclusion criteria: * patients ≥ 18 years * histologically confirmed inoperable locally advanced, recurrent, or metastatic adenocarcinoma of the stomach or gastro-oesophageal junction; * ecog (eastern cooperative oncology group) performance status 0-2; * adequate renal, hepatic, and hematologic function; * measurable or nonmeasurable disease according to the response evaluation criteria in solid tumors (recist). patients with intraoperatively confirmed intraperitoneal metastases but without detectable disease in radiological studies were also eligible exclusion criteria: * her2- positive tumors defined as either ihc 3+ or ihc 2+, the latter in combination with fish+ * previous chemotherapy for metastatic or locally advanced disease * surgery \<3 weeks before the onset of the study treatment * congestive heart failure * significant dysphagia that would preclude oral administration of capecitabine * concurrent malignant disease, except for adequately treated tumors with high likelihood of being cured (e.g. basal cell carcinoma of the skin, cervical cancer) * clinical evidence of brain metastases

Keywords: her2-negative gastric and gej adenocarcinoma first-line palliative chemotherapy eox mdcf efficacy safety
dextromethorphan as a novel non-opioid adjunctive agent for pain control in medication abortion

Conditions: Abortion in First Trimester

Summary: this study evaluates dextromethorphan as a non-opioid adjunctive medication for pain control during medication abortion. this is double-blinded, four-arm randomized controlled trial enrolling 156 women over a period of 9-12 months: receiving narcotics+dextromethorphan, narcotics and placebo (microcrystalline cellulose), no narcotics and dextromethorphan and no narcotics and placebo (microcrystalline cellulose).

medication abortion using mifepristone and misoprostol is common, accounting for nearly one-third of abortions in the united states in 2014. although women generally tolerate medical abortion well, pain and bleeding are common and expected side effects. up to a quarter of women rate their pain as severe during their procedure. pain management for medical abortion is challenging given that the most acute pain occurs at home rather than under the supervision of medical professionals. currently there is insufficient evidence to recommend an optimal regimen for pain control in medication abortion and there are concerns surrounding narcotic prescribing and the opiate abuse epidemic. this is a four-arm, prospective, double-blind, randomized controlled trial comparing dextromethorphan administration in conjunction with the current standard regimen (nsaids and narcotic medication by request- commonly oxycodone or codeine) to the standard regimen alone. pain will be evaluated by analgesia usage and self-reported pain scores. investigators will also investigate factors influencing pain and subjective components of the patient narrative. ideally, a non-opioid adjunct to nsaids or narcotics could be used to control pain and significantly curtail or avoid opioid use. investigators seek to test the efficacy and safety of dextromethorphan as a non-narcotic analgesic for medication abortion.

Eligibility criteria:
inclusion criteria: * women aged 18 and over * willing to give voluntary consent * english-speaking * eligible for medication abortion per planned parenthood of western pennsylvania protocol * self-reported reliable cellular phone access for the duration of study participation * able to receive and reply to a "test" text at time of consent * willing to comply with the study protocol exclusion criteria: * use of selective serotonin reuptake inhibitors or monoamine oxidase inhibitors due to risk of serotonin syndrome * allergy to any component of the medication abortion regimen or study drug * has any other condition that, in the opinion of the investigator, would preclude informed consent, make study participation unsafe, complicate the interpretation of the study outcome data, or otherwise interfere with achieving the study objectives * anticipated use of dextromethorphan during study period

Keywords: medication abortion dextromethorphan pain control
effect of theta burst transcranial magnetic stimulation on patients with dysphagia after stroke

Conditions: Stroke; Dysphagia; Functional Near- Infrared Spectroscopy; Transcranial Magnetic Stimulation

Summary: the purpose of this study was to observe the effect of theta burst transcranial magnetic stimulation (tbs) on swallowing function in patients with dysphagia after stroke (psd). functional near- infrared spectroscopy (fnirs) was used to detect the changes in activation and functional connectivity of related brain regions in psd patients treated with intermittent tbs（itbs）stimulation on the affected side and consistent tbs（ctbs） stimulation on the healthy side. to investigate the effects of tbs on swallowing related cortical excitability in stroke patients with dysphagia and explore its possible mechanism, and provide theoretical basis for the treatment of psd patients.


Eligibility criteria:
inclusion criteria: * age 18-80 years old * the first stroke lasted from 2 weeks to 6 months, with stable vital signs and right-handedness * the stroke met the diagnostic criteria of "chinese guidelines for the diagnosis and treatment of cerebral hemorrhage 2019" or "guidelines for the diagnosis and treatment of acute ischemic stroke 2018" formulated by the cerebrovascular department of the branch of neurology of the chinese medical association, and the cerebral ct or mri examination showed unilateral cerebral infarction or cerebral hemorrhage. * the dysphagia was consistent with the expert consensus on the evaluation and treatment of dysphagia in china (2017 edition), and the dysphagia was confirmed by videofluoroscopic swallowing study. * mmse\>24, good cognitive function * the skull is intact without craniotomy or repair * subject or family members sign informed consent exclusion criteria: * combined with other diseases that may cause swallowing disorders, such as parkinson's disease, dementia, motor neurone disease and other neurological diseases, or esophageal, neck surgery and other diseases that cause swallowing organ structure abnormalities * a history of mental illness or epilepsy * a metal implant in the head or eye, a pacemaker or a drug pump in the body * pregnancy, malignant tumor, serious disease history of heart, liver, kidney and other important organs * ulceration or infection of the skin on the head or where the electrode is applied * poor compliance and inability to complete basic treatment
l-glutamine therapy for sickle cell anemia

Conditions: Sickle Cell Anemia; Thalassemia

Summary: the primary purpose is to evaluate the effect of l-glutamine therapy on exercise endurance and breath by breath exercise response of sickle cell anemia patients the secondary purpose is to assess the effect of l-glutamine on incidence of painful crises; level of chronic pain, and amount of daily requirement for narcotics.

this is a phase ii, prospective, randomized, double-blind, placebo-controlled, parallel-group,study to evaluate the safety and efficacy of oral l-glutamine therapy for patients with sickle cell anemia or sickle β°-thalassemia who are at least 18 years old with focus on the aspect of exercise endurance. in this study, the patients will orally take l-glutamine or placebo twice daily, and clinical and hematological parameters will be monitored. the adverse events,especially those attributable to l-glutamine therapy, will also be monitored. the data obtained will be essential in understanding the role of l-glutamine in therapy for sickle cell anemia and sickle β°-thalassemia.

Eligibility criteria:
inclusion criteria: to be eligible to participate in the study, a patient must meet all of the following inclusion criteria: * patient is at least 18 years of age. * patient has been diagnosed with sickle cell anemia or sickle ß0-thalassemia (documented by hemoglobin electrophoresis). * patient has had at least two episodes of painful crises within 12 months of the screening visit. * if the patient has been treated with an anti-sickling agent within three months of the screening visit, the therapy must have been continuous for at least three months with the intent to continue for the next 14 months. * patient or the patient's legally authorized representative has given written informed consent. * if the patient is a female of child-bearing potential, she agrees to practice a recognized form of birth control during the course of the study. * patient is able to perform exercise tolerance test exclusion criteria: if the patient meets any of the following criteria, the patient must not be enrolled: * patient has a significant medical condition that required hospitalization (other than sickle painful crisis) within two months of the screening visit. * patient has diabetes mellitus with untreated fasting blood sugar \>115 mg/dl. * patient has prothrombin time international normalized ratio (inr) \> 2.0. * patient has serum albumin \< 3.0 g/dl. * patient has received any blood products within three weeks of the screening visit. * patient has a history of uncontrolled liver disease or renal insufficiency. * patient is pregnant or lactating. * patient has been treated with an experimental anti-sickling medication/treatment (except hydroxyurea) within 30 days of the screening visit. * patient has been treated with an experimental drug within 30 days of the screening visit. * there are factors that would, in the judgment of the investigator, make it difficult for the patient to comply with the requirements of the study.

Keywords: sickle cell disease sickle cell anemia l-glutamine sickle cell anemia (homozygous) sickle β°-thalassemia
cast or epineural suture for digital nerve injuries - a randomised controlled study

Conditions: Digital Nerve Injury

Summary: nerve injury in the fingers is a common injury and affects people of all ages. the treatment usually offered to patients is surgery and various types of rehabilitation. there is a lack of knowledge and research on how these injuries should be treated in the best way and how well sensory function can be restored after an injury. in this research project, we will investigate results after treatment for digital nerve injuries by entailing a randomised controlled trial allocating patients with isolated digital nerve injuries to either surgical repair or non-operative treatment in a cast. primary outcome is digital nerve function as measured by 2-points discrimination at 1 year after treatment. secondary outcomes include finger mobility, dexterity, handfunction, occurence of pain and anxiety and time on sick leave.

patients over the age of 20 with an acute traumatic isolated digital nerve injury to any of the fingers and not in the thumb will be investigated for inclusion in the study. after informed written consent a sealed envelope randomisation will allocate patients to treatment with either surgical exposure and epineural suture or non-operative treatment in a cast. due to the nature of treatment arms the allocation will not be blinded. clinical follow-up and investigation of primary and secondary outcomes will be conducted at 3 weeks, 3 months, 6 months and 1 year after inclusion.

Eligibility criteria:
inclusion criteria: * clinical signs of isolated traumatic digital nerve injury in digits 2, 3, 4 or 5. * patient age =\> 20 years on day of injury. * injury location on volar aspect of finger. * acute sensory dysfunction in suspected digital nerve injury area. exclusion criteria: * digital nerve injury ot the thumb * digital nerve injury in the palm of the hand (i e proximal to the finger base) * patient does not speak or read the swedish language. * abusive drug or alcohol use * dementia. * injury mor than 7 days at dianosis and/or operative treatment cannot be offered within 10 days from injury. * neurologic disease. * ongoing infektion in the injured finger. * concomittant tendoninjury or fracture in injured or adjacent finger. * injury mechanism is of blunt or crush charachter

Keywords: digital nerve injury digital nerve lesion randomised controlled study surgical nerve repair non-operative treatment
exercise versus niacin in patients with coronary artery disease (cad) and low high-density lipoproteins (hdl)

Conditions: Coronary Disease; Hypolipoproteinemia

Summary: the investigators want to study the relative effects of physical exercise vs. extended-release niacin (lipid-lowering drug) in patients with coronary heart disease and low hdl cholesterol ("good cholesterol") on * lipid profile * endothelial function as measured by ultrasound the endothelium is the inner part of the blood vessels. impaired endothelial function is known to be associated with atherosclerosis which can ultimately lead to diseases such as stroke, heart attack and others. endothelial function can be assessed non-invasively by ultrasound. both interventions mentioned above have been shown to have a beneficial effect on lipid profile and endothelial function. however, the relative effects are unclear.

comparison of physical exercise vs. extended-release niacin in patients with cad and low hdl cholesterol (\< 1,03 mmol/l) on lipid profile and endothelial function as measured by flow-mediated dilatation of radial artery. secondary goals are the assessment of biochemical markers of atherosclerosis, expression of monocyte surface markers, oxidative stress and thrombogenicity.

Eligibility criteria:
inclusion criteria: * coronary disease * low hdl cholesterol * age limits (see below) exclusion criteria: * unstable angina oder mi within 3 months prior to inclusion * cad with indication for bypass surgery * left main disease ( \> 25% stenosis diameter) * ejection fraction \< 40% * higher degree heart valve disease * higher degree ventricular arrhythmias * type 1 diabetes * severe disorders of lipoprotein metabolism (low-density lipoprotein cholesterol (ldl)\> 5.0 mmol/l) * severe liver disease * thyroid disease * alcohol or drug abuse * pregnancy * stroke or transient ischemic attack (tia) within 3 months prior to inclusion * allergy against niacin oder other ingredient of niaspan * participation in other clinical trial within 30 days prior to inclusion * acute gastric ulcer * arterial bleeding * uncontrolled severe arterial hypertension * treatment with lipid-lowering drug other than hydroxy-methylglutaryl coenzyme a (hmg-coa)-inhibitor within 3 months prior to inclusion
static balance disorders in patients after surgical treatment of hip acetabular fractures

Conditions: Hip Fractures; Acetabular Fracture; Balance; Distorted; Disability Physical

Summary: the mechanism of maintaining balance is a complex phenomenon, involving numerous systems of human body. high-energy trauma resulting in acetabular fracture damages some of the elements composing this delicate mechanism, potentially increasing the risk of falls in patients. there have not been any studies so far on balance levels in patients after surgical treatment of acetabular fractures. questions/purposes 1. do balance disorders occur in patients after orif of acetabular fractures? 2. do surgical approach and fracture pattern influence balance level of patients? 3. should therapy programs include certain stabilometric parameters adequate especially for this type of injury?

methods between 2014-2017, investigators evaluated 110 subjects: 55 patients after surgical treatment of acetabular fracture - the study population (mean age 43.6 ± 14.8 years) and 55 healthy subjects - the clinical control group (mean age 43.8 ± 14.9 years). to ensure reliability of results, controls were individually matched to appropriate study population patients, in terms age, sex, body height and mass. the study was conducted in public hospital and the protocol was approved by the commission of ethics (ske 01-21/2014). investigators measured static balance in double leg stance (eyes open/eyes closed) for 30s on cqstab2p, a double module stabilometric platform. the pain component of the harris hip score and the quality of fracture reduction (according to matta's criteria) in digitized anteroposterior and two oblique view radiographs were analyzed.

Eligibility criteria:
inclusion criteria: * written consent to participate in the study, * full legal age, * surgically treated hip acetabular fracture, * time after the surgery between 3 and 84 months, * full cognitive abilities, -full medical documentation, - the ability to fully load the operated limb (doctor's consent). exclusion criteria: * craniocerebral injuries, * visual system disorders, * neurological disorders, * ear and sinuses infections, * spinal pain * injuries to the lower extremities, * chronic illnesses (cancer, parkinson's disease, epilepsy, diabetes, neuro-muscular disorders, uncontrolled coronary heart disease), * taking psychoactive substances, * lower limb thrombosis
the obese taste bud study

Conditions: Obesity

Summary: the sense of taste is essential for priming food preferences and is therefore important for caloric uptake and body weight regulation. recent studies show that obesity is linked to changes in taste sensation but also to a loss of taste buds on the tongue. this study aims to evaluate underlying mechanisms within the taste buds to potentially influence the sense of taste on the level of these sensory cells and in order to develop new treatment strategies to fight obesity.


Eligibility criteria:
inclusion criteria: * normal weight (bmi 18.5-24.9) * obesity (bmi \>=30) * overall healthy (no severe sickness, no cancer) * written informed consent exclusion criteria: * current pregnancy or currently breastfeeding * cancer or tumors * state after radiotherapy at head-neck area * state after or current chemotherapy * severe psychiatric-, cardiac-, kidney- or neurological illness * diagnosed diabetes mellitus * known dysfunction of smelling or tasting * drug or alcohol abuse * permanent medication with antidepressants, anticonvulsants, steroids and/or immunosuppressants

Keywords: obesity food preferences taste disorder taste bud metabolic disease feeding behavior
comparison of different desensitizers in reducing dentinal hypersensitivity

Conditions: Dentine Hypersensitivity

Summary: this is a single center, randomized control. sixty eligible subjects will be recruited into 3 study treatment groups (n=20 per group) through computerized randomization. subjects in group 1 will be treated with 8% arginine containing paste(colgate® sensitive pro-relief™), group 2 with 5% topical fluoride varnish (acclean) and group 3 with self-adhesive resin (seal and protect, dentsply). the subjects in the study will be evaluated for tactile and air-blast hypersensitivity criteria at baseline, two and four weeks.

the aim of the present study is to evaluate the efficacy of three common professionally applied desensitizing agents in the reduction of dentine hypersensitivity over a period of 4 weeks. patients presenting to the dental clinic with dentine hypersensitivity and fulfilling the inclusion criteria will be included in the study after taking informed consent. participants will be divided into three groups. sixty eligible subjects will be recruited into 3 study treatment groups (n=20 per group) through computerized randomization. subjects in group 1 will be treated with 8% arginine containing paste(colgate® sensitive pro-relief™), group 2 with 5% topical fluoride varnish (acclean) and group 3 with self-adhesive resin (seal and protect, dentsply). the subjects in the study will be evaluated for tactile and air-blast hypersensitivity criteria at baseline, two and at four weeks by another dentist who would be a blind assessor.

Eligibility criteria:
inclusion criteria: * patients with age 18 and above with dentine hypersensitivity will be selected. * at least two hypersensitive teeth which will be sensitive to air blast (schiff air sensitivity scores of 2 or 3) and positive tactile sensitivity assessed clinically with explorer * written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study. exclusion criteria: * • patients who would have undergone any periodontal procedure or gotten any professionally applied desensitizers in the last three months. * patients having generalized sensitivity in all teeth * chronic use of anti-inflammatory and analgesic medications * pregnant or lactating females; * any denture bridgework; active cervical caries or deep abrasion requiring class v fillings; * fractured, crowned or root filled teeth and teeth with large restorations * carious teeth or cracked teeth assessed on the basis of clinical judgment

Keywords: dentine hypersensitivity fluoride varnish desensitizing agents